InMed Pharmaceuticals Inc. INM

What this company does

Together with BayMedica, our manufacturing capabilities include traditional approaches such as chemical synthesis and biosynthesis, as well as a proprietary, integrated manufacturing approach called IntegraSyn. BayMedica’s commercial business specializes in the B2B commercialization of bulk rare, non-intoxicating cannabinoids as raw materials for the Health and Wellness sector that are bioidentical to those found in nature. We were originally incorporated in the Province of British Columbia, under the Business Corporations Act (British Columbia) (the “BCBCA”), on May 19, 1981 (the “Incorporation Date”), and we have undergone a number of executive management, corporate name and business sector changes since such Incorporation Date, ultimately changing our name to “InMed Pharmaceuticals Inc.” on October 6, 2014. As of September 12, 2025, inclusive of our management team, we had 13 full-time employees, and we also utilize the services of several consultants.

Written from the business description in InMed Pharmaceuticals Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 September 2025. Every sentence was checked against that document before publication.